Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
12/05/2016 12/06/2016 12/07/2016 12/08/2016 12/09/2016 Date
3.7 3.74 3.77 3.8 3.835 Last
5435 8900 11538 23365 9681 Volume
+2.78% +1.08% +0.80% +0.80% +0.92% Change
Financials ( CAD)
Sales 2016 32,5 M
EBIT 2016 -19,3 M
Net income 2016 -24,8 M
Debt 2016 -
Yield 2016 -
Sales 2017 41,0 M
EBIT 2017 -9,21 M
Net income 2017 -11,4 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 3,76x
Capi. / Sales2017 2,98x
Capitalization 122 M
More Financials
Company
Cardiome Pharma Corp. is a specialty pharmaceutical company.It engages in the discovery, development and commercialization of cardiovascular therapies that will improve the health of patients suffering from heart disease.Cardiome has two marketed products, BRINAVESS, approved in Europe and other... 
Sector
Pharmaceuticals
Calendar
03/16Earnings Release
More about the company
Surperformance© ratings of Cardiome Pharma Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on CARDIOME PHARMA CORP
12/08 CARDIOME PHARMA : Announces Commercial Launch of Xydalba(TM) (dalbavancin) in th..
11/29 CARDIOME PHARMA : Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch
11/07 CARDIOME PHARMA : Reports Third Quarter 2016 Financial Results
11/01 CARDIOME PHARMA : to Reschedule Release of Third Quarter 2016 Financial Results
10/28 CARDIOME PHARMA : to Hold Third Quarter 2016 Financial Results Conference Call o..
10/14 CARDIOME PHARMA : Announces Initiation of Commercial Operations in Canada, Eh
08/16 CARDIOME PHARMA : Announces Recent Insider Purchases
08/09 CARDIOME PHARMA : Reports Second Quarter 2016 Financial Results
08/09 CARDIOME PHARMA : Announces XYDALBA(TM) Single Dose Infusion Approval by Europea..
08/08 CARDIOME PHARMA : Announces the Addition of Two Key Members to its Management Te..
More news
Sector news : Biopharmaceuticals
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
More sector news : Biopharmaceuticals
News from SeekingAlpha
11/09 Cardiome Pharma's (CRME) CEO Dr. Bill Hunter on Q3 2016 Results - Earnings Ca..
11/07 Cardiome Pharma beats by $0.01, misses on revenue
11/06 Notable earnings before Monday?s open
08/10 Cardiome Pharma's (CRME) CEO Bill Hunter on Q2 2016 Results - Earnings Call T..
08/10 Single-dose regimen for Cardiome's Xydalba OK'd in Europe
Advertisement
Chart CARDIOME PHARMA CORP
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 11,3  CAD
Spread / Average Target 195%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Jennifer Archibald Chief Financial Officer
Harold H. Shlevin Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP-63.64%93
BIOGEN INC-5.49%62 611
CSL LIMITED-9.79%32 310
ALEXION PHARMACEUTICAL..-30.76%29 616
BIOMARIN PHARMACEUTICA..-21.08%14 220
GRIFOLS SA-17.50%11 817
More Results